Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:https://doi.org/10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–2413. doi:https://doi.org/10.1200/JCO.1997.15.6.2403
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi:https://doi.org/10.1056/NEJMoa1011923
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:https://doi.org/10.1056/NEJMoa1304369
   PubMed Web of Science ®Google Scholar
• Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer. 2004;90(5):996–1002. doi:https://doi.org/10.1038/sj.bjc.6601620
   PubMed Web of Science ®Google Scholar
• Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, Giacosa A, Van Gossum A, Bauer J, Barber MD, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52(10):1479–1486. doi:https://doi.org/10.1136/gut.52.10.1479
   PubMed Web of Science ®Google Scholar
• Fearon KC, Barber MD, Moses AG. The cancer cachexia syndrome. Surg Oncol Clin N Am. 2001;10(1):109–126.
   PubMedGoogle Scholar
• Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105. doi:https://doi.org/10.1038/nrdp.2017.105
   PubMed Web of Science ®Google Scholar
• Evans WK, Nixon DW, Daly JM, Ellenberg SS, Gardner L, Wolfe E, Shepherd FA, Feld R, Gralla R, Fine S, et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol. 1987;5(1):113–124. doi:https://doi.org/10.1200/JCO.1987.5.1.113
   PubMed Web of Science ®Google Scholar
• Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol. 1993;11(10):2043–2049. doi:https://doi.org/10.1200/JCO.1993.11.10.2043
   PubMed Web of Science ®Google Scholar
• Beck SA, Smith KL, Tisdale MJ. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res. 1991;51(22):6089–6093.
   PubMed Web of Science ®Google Scholar
• Murphy RA, Mourtzakis M, Chu QSC, Baracos VE, Reiman T, Mazurak VC. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer. 2011;117(16):3774–3780. doi:https://doi.org/10.1002/cncr.25933
   PubMed Web of Science ®Google Scholar
• Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69(12):1375–1381.
   PubMedGoogle Scholar
• Caillet P, Liuu E, Raynaud Simon A, Bonnefoy M, Guerin O, Berrut G, Lesourd B, Jeandel C, Ferry M, Rolland Y, et al. Association between cachexia, chemotherapy and outcomes in older cancer patients: a systematic review. Clin Nutr. 2017;36(6):1473–1482. doi:https://doi.org/10.1016/j.clnu.2016.12.003
   PubMed Web of Science ®Google Scholar
• Punzi T, Fabris A, Morucci G, Biagioni P, Gulisano M, Ruggiero M, Pacini S. C-reactive protein levels and vitamin d receptor polymorphisms as markers in predicting cachectic syndrome in cancer patients. Mol Diagn Ther. 2012;16(2):115–124. doi: https://doi.org/10.2165/11632380-000000000-00000.
   PubMedGoogle Scholar
• Baumgartner RN, Koehler KM, Romero L, Garry PJ. Serum albumin is associated with skeletal muscle in elderly men and women. Am J Clin Nutr. 1996;64(4):552–558. doi:https://doi.org/10.1093/ajcn/64.4.552
   PubMedGoogle Scholar
• Solheim TS, Laird BJA, Balstad TR, Bye A, Stene G, Baracos V, Strasser F, Griffiths G, Maddocks M, Fallon M, et al. Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support Palliat Care. 2018;8(3):258–265. doi:https://doi.org/10.1136/bmjspcare-2017-001440
   PubMed Web of Science ®Google Scholar
• Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer. 2008;44(8):1124–1132. doi:https://doi.org/10.1016/j.ejca.2008.02.033
   PubMed Web of Science ®Google Scholar
• Ministry of Education, Culture, Sports, Science and Technology (MEXT). Office for Resources, Policy Division Science and Technology Policy Bureau [Internet]. Standard Tables of Food Composition in Japan Seventh Revised Edition. MEXT; 2015. https://www.mext.go.jp/en/policy/science_technology/policy/title01/detail01/1374030.htm [last accessed 2015 Jan 27].
   Google Scholar
• Akita H, Takahashi H, Asukai K, Tomokuni A, Wada H, Marukawa S, Yamasaki T, Yanagimoto Y, Takahashi Y, Sugimura K, et al. The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: prospective randomized control study. Clin Nutr Espen. 2019;33:148–153. doi:https://doi.org/10.1016/j.clnesp.2019.06.003
   PubMed Web of Science ®Google Scholar
• Pezzilli R, Caccialanza R, Capurso G, Brunetti O, Milella M, Falconi M. Pancreatic enzyme replacement therapy in pancreatic cancer. Cancers (Basel). 2020;12(2):275. doi:https://doi.org/10.3390/cancers12020275
   Web of Science ®Google Scholar
• Ueno M, Okusaka T, Omuro Y, Isayama H, Fukutomi A, Ikeda M, Mizuno N, Fukuzawa K, Furukawa M, Iguchi H, et al. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancerdagger. Ann Oncol. 2016;27(3):502–508. doi:https://doi.org/10.1093/annonc/mdv603
   PubMedGoogle Scholar